MANKIND PHARMA LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,140 INR | +2.18% |
|
+3.73% | +7.93% |
| 30/05 | Advent International Receives 6-7 Bids for Bharat Serums | CI |
| 16/05 | Transcript : Mankind Pharma Limited, Q4 2024 Earnings Call, May 16, 2024 |
| Sales 2024 | 10TCr 123.9Cr | Sales 2025 * | 12TCr 139.47Cr | Capitalization | 86TCr 1.03TCr |
|---|---|---|---|---|---|
| Net income 2024 | 1.91TCr 23Cr | Net income 2025 * | 2.21TCr 26Cr | EV / Sales 2024 | 8.92 x |
| Net cash position 2024 * | 2.53TCr 30Cr | Net cash position 2025 * | 4.35TCr 52Cr | EV / Sales 2025 * | 6.99 x |
| P/E ratio 2024 |
48.3
x | P/E ratio 2025 * |
38.8
x | Employees | 18,468 |
| Yield 2024 * |
0.29% | Yield 2025 * |
0.41% | Free-Float | 19.92% |
More Fundamentals
* Assessed data
More news
Latest transcript on Mankind Pharma Limited
More recommendations
| 1 day | +2.18% | ||
| 1 week | +3.73% | ||
| 1 month | -9.50% | ||
| 3 months | +0.19% | ||
| 6 months | +12.76% | ||
| Current year | +7.93% |
1 week
2 063.85
2 200.00
1 month
2 056.002 399.05
Current year
1 980.002 490.00
1 year
1 399.052 490.00
3 years
1 242.002 490.00
5 years
1 242.002 490.00
10 years
1 242.002 490.00
| Managers | Title | Age | Since |
|---|---|---|---|
Sheetal Arora
CEO | Chief Executive Officer | 48 | 21/07/21 |
Ashutosh Dhawan
DFI | Director of Finance/CFO | 55 | 17/16/17 |
Pradeep Chugh
CMP | Compliance Officer | - | 23/16/23 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Vivek Kalra
BRD | Director/Board Member | 60 | 01/22/01 |
Vijaya Sampath
BRD | Director/Board Member | 71 | 01/22/01 |
Surendra Lunia
BRD | Director/Board Member | 61 | 19/15/19 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 31/24/31 | 2,140 | +2.18% | 13,650,650 |
| 30/24/30 | 2,094 | -0.39% | 1,342,025 |
| 29/24/29 | 2,102 | -0.57% | 781,782 |
| 28/24/28 | 2,114 | +0.00% | 610,496 |
| 27/24/27 | 2,114 | +2.50% | 959,693 |
Delayed Quote NSE India S.E., May 31, 2024 at 05:13 pm IST
More quotes
Mankind Pharma Limited is an India-based pharmaceutical company. The Company is engaged in developing, manufacturing, and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. The Company offers exceptional healthcare solutions for a wide range of healthcare needs with a diverse portfolio that includes anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/ central nervous system (CNS), vitamins, minerals and nutrients and respiratory therapies. Its portfolio of brands includes Nurokind, Telmikind, Manforce (Rx), Gudcef, Moxikind, Amlokind, Glimestar, Asthakind, Codistar, Candiforce, Mahacef, Dydroboon, Cefakind, Zenflox, Monticope, Dynaglipt, and others. The Company's subsidiaries include Lifestar Pharma Private Limited, Magnet Labs Private Limited, Broadway Hospitality Services Private Limited, Jaspack Industries Private Limited, and others.
Sector
Pharmaceuticals
Calendar
04/06/2024
- BofA India Conference
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
2,140
INR
Average target price
2,237
INR
Spread / Average Target
+4.54%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +7.93% | 1.03TCr | |
| +40.73% | 74TCr | |
| +32.83% | 60TCr | |
| -6.30% | 35TCr | |
| +15.15% | 32TCr | |
| +4.05% | 28TCr | |
| +15.00% | 24TCr | |
| +9.78% | 21TCr | |
| -5.52% | 21TCr | |
| +6.17% | 16TCr |
- Stock Market
- Equities
- MANKIND Stock
